1. Adding chemotherapy to immunotherapy did not prolong OS or PFS, with non-significant differences in HR. 2. Grade 3 or higher immune-related adverse events occurred in 24.3% and 17.9% in the ICI-chemotherapy and ICI-alone groups. Evidence Rating Level: 2 (Good) Study Rundown: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in non-small cell lung cancer